XML 45 R26.htm IDEA: XBRL DOCUMENT
v3.3.1.900

BUSINESS SEGMENT INFORMATION | 12 Months Ended
--- | ---
Dec. 31, 2015
Segment Reporting [Abstract] |
BUSINESS SEGMENT INFORMATION | BUSINESS SEGMENT INFORMATION The Company's DIS business provides insights through clinical testing and related services to patients, physicians, hospitals, ACOs, IDNs, health plans, employers and others. The Company is the world's leading provider of diagnostic information services, which includes providing clinical testing services such as routine (including drugs-of-abuse) testing, gene-based and esoteric testing, and anatomic pathology services, as well as related services and insights. The DIS business accounted for greater than 90% of net revenues from continuing operations in 2015, 2014 and 2013. All other operating segments include the Company's DS businesses, which consists of its risk assessment services, clinical trials testing, diagnostic products and healthcare information technology businesses (see Note 6 regarding the contribution of the clinical trials testing business to a newly formed joint venture effective July 1, 2015 and non-core assets held for sale). The Company's DS businesses offer a variety of solutions for life insurers, healthcare providers and others. During 2015, the Company acquired certain operations of MemorialCare and Superior Mobile Medics (see Note 5). MemorialCare is included in the Company's DIS business. Superior Mobile Medics is included in all other operating segments. During 2014, the Company acquired Solstas, Summit Health and Steward which are included in the Company's DIS business. During 2013, the Company acquired certain operations of UMass, ATN, Dignity and ConVerge which are included in the Company's DIS business. In addition, the Company completed the sale of Enterix in the third quarter of 2013, which is included in all other operating segments. On April 19, 2006, the Company decided to discontinue NID’s operations. The Company completed the sale of HemoCue in the second quarter of 2013. The results of operations for NID and HemoCue have been classified as discontinued operations for all periods presented (see Note 18). At December 31, 2015, substantially all of the Company’s services are provided within the United States, and substantially all of the Company’s assets are located within the United States. The following table is a summary of segment information for the years ended December 31, 2015, 2014 and 2013. Segment asset information is not presented since it is not used by the chief operating decision maker at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangibles assets, other operating income and expenses net of certain general corporate activity costs that are allocated to the DIS and DS businesses, and the third quarter of 2015 pre-tax gain on contribution of business to joint venture (see Note 6), the third quarter of 2013 pre-tax gain on the sale of the ibrutinib royalty rights and the pre-tax loss on the sale of Enterix. The accounting policies of the segments are the same as those of the Company as set forth in Note 2.
| 2015 |  | 2014 |  | 2013
Net revenues: |  |  |  |  |  |  |
DIS business | $ | 6,965 |  |  | $ | 6,873 |  |  | $ | 6,587 |
All other operating segments | 528 |  |  | 562 |  |  | 559 |
Total net revenues | $ | 7,493 |  |  | $ | 7,435 |  |  | $ | 7,146 |
Operating earnings (loss): |  |  |  |  |  |  |
DIS business | $ | 1,118 |  |  | $ | 1,068 |  |  | $ | 1,201 |
All other operating segments | 110 |  |  | 94 |  |  | 76 |
General corporate activities | 171 |  |  | (179 | ) |  | 198 |
Total operating income | 1,399 |  |  | 983 |  |  | 1,475 |
Non-operating expenses, net | (296 | ) |  | (160 | ) |  | (151 | )
Income from continuing operations before income taxes and equity in earnings of equity method investees | 1,103 |  |  | 823 |  |  | 1,324 |
Income tax expense | (373 | ) |  | (262 | ) |  | (500 | )
Equity in earnings of equity method investees, net of taxes | 23 |  |  | 26 |  |  | 24 |
Income from continuing operations | 753 |  |  | 587 |  |  | 848 |
Income from discontinued operations, net of taxes | — |  |  | 5 |  |  | 35 |
Net income | 753 |  |  | 592 |  |  | 883 |
Less: Net income attributable to noncontrolling interests | 44 |  |  | 36 |  |  | 34 |
Net income attributable to Quest Diagnostics | $ | 709 |  |  | $ | 556 |  |  | $ | 849 |
| 2015 |  | 2014 |  | 2013
Depreciation and amortization: |  |  |  |  |
DIS business | $ | 212 |  |  | $ | 206 |  |  | $ | 189 |
All other operating segments | 10 |  |  | 13 |  |  | 12 |
General corporate | 82 |  |  | 95 |  |  | 82 |
Total depreciation and amortization | $ | 304 |  |  | $ | 314 |  |  | $ | 283 |
Capital expenditures: |  |  |  |  |
DIS business | $ | 243 |  |  | $ | 283 |  |  | $ | 196 |
All other operating segments | 16 |  |  | 17 |  |  | 26 |
General corporate | 4 |  |  | 8 |  |  | 9 |
Total capital expenditures | $ | 263 |  |  | $ | 308 |  |  | $ | 231 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration